Tools for Enabling Process Analytical Technology Applications in Biotechnology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tools for Enabling Process Analytical Technology Applications in Biotechnology
The success of process analytical technology (PAT), a recent initiative by FDA, depends to a large extent on efficient control of manufacturing processes to achieve predefined quality of the final product. In this paper, the authors review the various analytical methods that can enable use of PAT.


Pharmaceutical Technology
pp. s16-s22, s28-s31

References

1. FDA, PAT Guidance for Industry— A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance, September, (2004).

2. E.K. Read et al., Biotechnol. Bioengin. 105, 276–284 (2010).

3. E.K. Read et al, Biotechnol. Bioengin. 105, 285–295 (2010).

4. A.S. Rathore and H. Winkle, Nat. Biotechnol. 27, 26–34 (2009).

5. A.S. Rathore, R. Bhambure, and V. Ghare, Anal. Bioanal. Chem. 398, 137–154 (2010).

6. W.F. McClure et al., Near-Infrared Technology in the Agricultural and Food Industries, 2, 145–169 (2001).

7. Handbook of Near-Infrared Analysis, D.A. Burns and E.W. Ciurczak, Eds. (CRC Press, Taylor & Francis Group, Boca Raton, Florida, 2001) 22, 573–575.

8. M. Roman Balabin, Z. Ravilya Safieva, and I. Ekaterina Lomakina, Chemometr. Intell. Lab 2, 183–188 (2007).

9. A.O. Kirdar, G. Chen, and A.S. Rathore, Biotechnol. Prog. 26, 527–531 (2010).

10. S. Gnoth, M. Jenzsch, R. Simutis, and A. Lubbert, J. Biotechnol. 132, 180–186 (2007).

11. X. Lawrence Yu et al, Advan. Drug Del. Rev. 56, 349–369 (2004).

12. C. Dirk Hinz, Anal. and Bioanal. Chem. 384, 1036–1042 (2006).

13. P.J. Treado and M.D. Morris, Prac. Spectros. Series 16, (1993).

14. P. Matousek and A.W. Parker, Raman Spectrosc. 38, 563–567 (2007).

15. T.R.M. De Beer et al., Anal. Chem. 79, 7992–8003 (2007).

16. http://www.brukeroptics.com/minispec.html.

17. I. Duarte et al., Agric. Food Chem. 50, 2475–2481 (2002).

18. C. Goudar et al., Metabolic Engin. 12, 138–149 (2010).

19. H. Metz and K. Mader, Inter. J. of Pharmaceutics 364, 170–175 (2008).

20. E. Heinzle and A. Oeggerli., Anal. Chim. Acta. 238, 101–115 (1990).

21. S. Chauvatcharins et al. Bioeng. 79, 264–269 (1995).

22. D. Smith and P. Španlm, Mass Spectrom. Rev. 24, 661–700, (2005).

23. F. Erni, J. of Chrom. 251, 141–151 (1982).

24. E.P.C. Lai, B.L.C., and S. Chen, App. Spec. 42, 381–529 (1988).

25. J. Medendorp and R.A. Lodder, PharmSciTech 7, 175–183 (2006).

26. G. Robert Buice, Jr., P. Pinkston, and A. Robert, Soc. for App. Spec. 48, 517–524 (1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here